other material
confidence high
sentiment negative
materiality 0.85
BIOCEPT INC: auditor change — Biocept restates Q1-Q3 2022 results due to errors in stock-based compensation and revenue recognition
BIOCEPT INC
- Errors included incorrect inputs in Black-Scholes calculation for options granted April 2019 and acceleration of stock-based compensation in Q1 2022.
- Revenue recognition errors: failure to reflect changes in payor class and implicit price concessions in Q2 and Q3 2022 financial statements.
- Management concluded that review controls over stock-based compensation and revenue recognition did not operate effectively, causing material errors.
- Restated quarterly financial statements are expected to be filed by April 17, 2023; previously issued Q1-Q3 2022 reports should no longer be relied upon.